The proceeds will be used to fund working capital and advance Protagenic's peptide-based drug candidates for stress and central-nervous-system disorders, according to a statement.

Meanwhile, the company said it executed a business combination with Phytanix Bio, integrating six programs under one company.

Price: 6.91, Change: +0.03, Percent Change: +0.39

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.